Current Pharmaceutical Design

William A. Banks  
VAPSHCS/GRECC S-182
Building 1, Room 810A
1600 S. Columbian Way
Seattle, WA 98108
USA

Back

Study on Gluco-Regulatory Potential of Glimepiride Sulfonamide Using In silico, In Vitro and In Vivo Approaches

Author(s): Hamendra Singh Parmar, Mahesh Kumar Bhinchar, Muskan Bhatia, Nikita Chordia, Ishan Raval, Digvijay Singh Chauhan, E. Manivannan, Rameshwar Jatwa, Anil Kumar.

Abstract:

Glimepiride sulfonamide (GS) is a drug intermediate to synthesize glimepiride (antidiabetic drug). We hypothesized that GS exerts gluco-regulatory effect because GS is comprised of the structural components of dipeptidyl peptidase-IV (DPP-IV) inhibitors sitagliptin and DPP-728and glimepiride (sulfonylurea based antidiabetic drug).We analyzed the drug-likeness and docking efficiency of GS with DPP-IV using in silico tools. Also DPP-IV inhibition assays were conducted in vitro. Gluco-regulatory potential and parameters of drug safety were evaluated on normal euglycemic and streptozotocin (STZ) induced diabetic rats. We observed strong drug-likeness and DPP-IV binding efficiency of GS. Similarly, profound DPP-IV inhibition was also observed in vitro. Studies on euglycemic and STZ induced diabetic rats revealed antidiabetic potential for GS without significant change in the studied toxicological parameters. Glimepiride sulfonamide has antidiabetic potential mainly through DPP-IV inhibition, but also through insulin stimulation and alpha-amylase inhibition

Keywords: Alanine amino transaminase, alpha-amylase, aspartate aminotransferase, diabetes, dipeptidyl peptidase-IV, insulin, lipid peroxidation, urea.

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

VOLUME: 20
ISSUE: 32
Year: 2014
Page: [5212 - 5217]
Pages: 6
DOI: 10.2174/1381612820666140318114832
Price: $58